Introduction
============

Transmembrane efflux pumps play an increasing role in the success of ART. The occurrence of increasing mRNA levels of the efflux pump proteins P-gp and MRP subtypes has been associated with ART therapeutics like PIs and NNRTIs. Moreover, a relation has been suggested of MRP subtypes and CD4 cell counts. So there is a challenge to find selective MRP inhibitors which may reduce MRP-induced drug resistances as well as discussed effects on CD4 cells. We developed novel nonpeptidic inhibitors of important MRP subtypes related to both MRP-mediated resistances as well as reduced cell counts.

Materials and methods
=====================

The molecular structures of the various efflux pumps guided the development of both symmetric and nonsymmetric inhibitors dedicated to selectively inhibit the relevant MRP-subtypes. Inhibiting properties were evaluated in exclusively P-gp as well as MRP-overexpressing cell lines in comparison to nonexpressing parental cell lines with fluorescent substrates using flow cytometry.

Results
=======

Our inhibitors with allover symmetric substitution patterns are excellent P-gp inhibitors, while a reduction of those symmetric elements concerning their number and exact positioning significantly lowers the P-gp inhibition whereas the MRP1 inhibition is found mainly increased. So selective inhibitors are demonstrated to influence the efflux pump type-related antiretroviral drug resistance.

Conclusions
===========

The success of ART may be mainly increased by selective MRP inhibitors which reduce the MRP-related effects on drug resistance as well as on discussed cell counts. Structure-guided studies of the efflux pump inhibition helped to design novel selective inhibitors with structure-reasoned effects of the nonsymmetric substitution patterns. So far only nonselective inhibitors have been used in ART with undesired effects on transporter-related pharmacokinetics. Selective inhibitors will mean a progress in ART especially with less limiting side effects.
